Pharmaceutical News

RSS

Study could lead to potential new therapeutic target with fewer side effects for hypertension

A team of Vermont investigators has been issued a patent for their discovery of a molecule that rescues damaged blood vessels, yet preserves healthy vessels and could serve as a springboard for a new pharmaceutical therapy with fewer side effects for hypertension - a major risk factor for cardiovascular and kidney disease that effects roughly one in three people in the U.S.

15 Mar 2016

Aralez resubmits NDA package for YOSPRALA to FDA

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.

15 Mar 2016

Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients.

15 Mar 2016

St. Jude scientists develop insights to guide development of powerful novel anti-influenza drugs

By analyzing the molecular details of how artificially created drug-resistant flu strains manage to survive treatment, St. Jude Children's Research Hospital scientists have developed insights to guide development of powerful new anti-influenza drugs. These compounds will target a viral enzyme critical to the virus' proliferation in the body.

15 Mar 2016

New drug shows promise against mesothelioma

A new drug is showing promise as a treatment for mesothelioma - one of the most lethal cancers of all.

15 Mar 2016

HIV drug could delay drug resistance, making skin cancer treatment effective for longer time

An HIV drug could stop one of the early changes in skin cancer cells that leads to them becoming resistant to treatment, according to a Cancer Research UK-funded study published in Cancer Cell today

15 Mar 2016

Heart failure drug has unexpected ability to block herpesvirus infection

Today, there is only one class of antiviral medicines against herpesviruses - a family of viruses that cause mononucleosis, herpes, and shingles, among other illnesses - meaning options for treating these infections are limited. If viruses become resistant to these frontline treatments, a growing problem particularly in clinical settings, there are no alternative drugs to serve as backup.

15 Mar 2016

New drug could transform treatment of metastatic triple negative breast cancer

A team of investigators from Houston Methodist Research Institute may have transformed the treatment of metastatic triple negative breast cancer by creating the first drug to successfully eliminate lung metastases in mice.

15 Mar 2016

Combination drug therapy may stop KRAS-mediated lung adenocarcinoma

Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.

15 Mar 2016

Drugs to help energy-starved photoreceptors offers new avenue for treating AMD , MacTel

New research from Boston Children's Hospital could potentially change how doctors approach two blinding diseases: 'Wet' age-related macular degeneration (AMD), the leading cause of blindness in the elderly, and macular telangiectasia (MacTel).

15 Mar 2016

Researchers aim to design a better male contraceptive pill

Women can choose from a wide selection of birth control methods, including numerous oral contraceptives, but there's never been an analogous pill for men. That's not for lack of trying: For many years, scientists have attempted to formulate a male pill. Finally, a group of researchers has taken a step toward that goal by tweaking some experimental compounds that show promise.

14 Mar 2016

NIH-funded investigators develop therapeutic compound effective against malaria

An international team that includes NIH-funded researchers at Stanford University has developed a therapeutic compound that is effective in inhibiting Plasmodium falciparum, one of five species of parasite that infects people with malaria, and the strain which causes the highest number of malaria deaths.

13 Mar 2016

Beta-blockers could have potential benefit for COPD patients

Beta-blockers could be used to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations, according to new findings.

13 Mar 2016

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.

13 Mar 2016

Research findings could help treat people with sexual disorders

Undesirable associations with sex can be unlearned, but return if the circumstances change. They must therefore be unlearned in different situations. The drug D-cycloserine may help here. These are the findings of psychologist Mirte Brom.

11 Mar 2016

New RI-MUHC-led study may change the way we think about prescribing statins

Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.

11 Mar 2016

Patients with early-stage NSCLC and low SMARCA4 expression may benefit from platinum-based chemotherapy

The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.

11 Mar 2016

STING agonists developed to induce cellular death in B cell malignancies

In almost every mammalian cell, you will find the endoplasmic reticulum, a network of continuous membranes responsible for controlling metabolism as well as the folding, assembly and secretion of proteins.

11 Mar 2016

Popular kidney cancer drugs do not reduce incidence of recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania.

10 Mar 2016

Scientists discover novel drug candidate to treat breast cancer, lung cancer and melanoma

Using a new approach, scientists at The Scripps Research Institute and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.

10 Mar 2016